<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01819519</url>
  </required_header>
  <id_info>
    <org_study_id>RFA-DD-12-005</org_study_id>
    <nct_id>NCT01819519</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Behavioral Modification to Prevent Congenital Cytomegalovirus</brief_title>
  <acronym>CDC/CMV</acronym>
  <official_title>Development and Evaluation of a Clinic-Based Screening and Brief Intervention for Changing Behaviors Related to Cytomegalovirus Transmission in Pregnant Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Women and Infants Hospital of Rhode Island</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Women and Infants Hospital of Rhode Island</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop a brief screening and behavioral intervention for the&#xD;
      prevention of congenital cytomegalovirus (CMV) that will both be acceptable to clinic staff&#xD;
      and feasible to implement as part of routine clinical prenatal care, and to test whether&#xD;
      behavioral intervention for susceptible pregnant women can lead to a behavioral change that&#xD;
      is likely to lead to decreased primary CMV infection. The study research assistants will&#xD;
      enroll pregnant women who are less than 20 weeks' gestation, either English or&#xD;
      Spanish-speaking and that do not have a primary CMV infection (never been infected or&#xD;
      previously infected). Enrollment will occur during the woman's prenatal visit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized single-masked clinical trial of behavioral intervention versus&#xD;
      standard care of pregnant women lacking evidence of acute CMV infection that have consented&#xD;
      to be screened as part of the Maternal Fetal Medicine Units Network multi-centered randomized&#xD;
      clinical trial, in which pregnant women are screened with CMV serology for IgM, IgG, and IgG&#xD;
      avidity.&#xD;
&#xD;
      Eligible pregnant women will be randomized to one of two treatment groups:&#xD;
&#xD;
        -  Control Group - no intervention&#xD;
&#xD;
        -  Intervention Group - brief intervention and educational materials Written informed&#xD;
           consent will be obtained from patients before they can be screened for the study by CMV&#xD;
           testing (IgM, IgG, and IgG avidity) as per the protocol for screening in the MFMU study.&#xD;
&#xD;
      All women presenting for prenatal care no later than 20 weeks gestational age without a known&#xD;
      multifetal gestation are eligible for CMV screening Those with evidence of primary infection&#xD;
      will be offered participation in the MFMU randomized trial of CMV hyperimmune globulin to&#xD;
      prevent congenital infection. Women lacking evidence of acute infection will be eligible for&#xD;
      randomization into this study. Patients must be randomized no later than 20 weeks gestation.&#xD;
&#xD;
      If eligible and no more than 20 weeks gestation, the patient will be randomized. If the&#xD;
      patient is randomized in the control group, she will continue her routine prenatal care&#xD;
      inclusive of the CDC brochure that she received at the time of her venipuncture for serologic&#xD;
      screening and assessment of hygiene behaviors. If the patient is randomized into the&#xD;
      intervention group, we will deliver a face-face educational intervention during her next&#xD;
      routine prenatal visit. In addition to the intervention, the patient will include educational&#xD;
      material to take home.&#xD;
&#xD;
      Both groups will be assessed for performance of hygiene behaviors as a baseline assessment at&#xD;
      the time of consent. A second assessment will occur at least 12 weeks after enrollment during&#xD;
      the third trimester between 28-36 weeks of gestation. The follow-up assessment will be&#xD;
      completed by a different research assistant from the unblinded educator. A Kessler 10 (K10)&#xD;
      survey will also be completed in addition to the baseline and follow-up assessment.&#xD;
&#xD;
      The follow-up assessment will take place during the participant's third trimester between&#xD;
      28-36 weeks of gestation, depending on duration of enrollment and likelihood of early&#xD;
      delivery. The enrollment duration will vary from approximately 14-20 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hygiene Behaviors</measure>
    <time_frame>Participants will be followed from enrollment (baseline) to 14-20 weeks after enrollment (follow-up)</time_frame>
    <description>The primary outcome is defined as a change in the participant's hygiene behaviors determined by the differences between the baseline and follow-up behavioral assessment compliance scores. Each question in these assessments will be assigned a score from 0-5 (5 = desired preventative behavior).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Behavior Change based on Serostatus</measure>
    <time_frame>Participants will be followed from enrollment (baseline) to 14-20 weeks after enrollment (follow-up)</time_frame>
    <description>Did knowing the serostatus affect hygiene behavior change, as defined by a change in compliance scores between baseline and follow-up visits?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in K10 after Intervention</measure>
    <time_frame>Participants will be followed from enrollment (baseline) to 14-20 weeks after enrollment (follow-up)</time_frame>
    <description>Was there a change in stress and anxiety (measured by the K10 assessment scores) before and after the intervention?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavior Change based on Socioeconomics</measure>
    <time_frame>Participants will be followed from enrollment (baseline) to 14-20 weeks after enrollment (follow-up)</time_frame>
    <description>Was behavior change influenced by socioeconomic status? Behavior change is defined by the difference in compliance scores between baseline and follow-up visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Racial associations with hygiene behavior change</measure>
    <time_frame>Participants will be followed from enrollment (baseline) to 14-20 weeks after enrollment (follow-up)</time_frame>
    <description>Was behavior change influenced by race? Behavior change is defined by the difference in compliance scores between baseline and follow-up visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavior Change related to Children at home</measure>
    <time_frame>Participants will be followed from enrollment (baseline) to 14-20 weeks after enrollment (follow-up)</time_frame>
    <description>Was behavior change influenced by the number of children living at home? Behavior change is defined by the difference in compliance scores between baseline and follow-up visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavior Change and Occupation Association</measure>
    <time_frame>Participants will be followed from enrollment (baseline) to 14-20 weeks after enrollment (follow-up)</time_frame>
    <description>Was behavior change influenced by participants' occupation? Behavior change is defined by the difference in compliance scores between baseline and follow-up visits</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">223</enrollment>
  <condition>Cytomegalovirus Infections</condition>
  <condition>Pregnancy</condition>
  <condition>Behavior</condition>
  <arm_group>
    <arm_group_label>Standard Prenatal Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will receive standard prenatal care from the time they are screened for CMV to delivery. This includes a CMV brochure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Educational Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will be approached during a routine prenatal visit and will receive a 5-10 minute educational intervention (CMV prevention video, preventive information, weekly text messages/emails as reminders for hygiene behaviors, developmental calendar with hygiene reminders).</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Educational Intervention</intervention_name>
    <description>The patient will told if previously infected or seronegative and what is the risk of the becoming infected. The research assistant will deliver a 5-10 minutes educational intervention, which will consist of a CMV video and some Q&amp;A.</description>
    <arm_group_label>Educational Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women lacking evidence of acute CMV infection is defined as one of the&#xD;
             following: A negative IgM antibody (&lt;1.00 Index) and negative IgG antibody (&lt;6.0&#xD;
             AU/ml) or A negative IgM antibody (&lt;1.00 Index) and positive IgG antibody (â‰¥6.0 AU/ml)&#xD;
&#xD;
          -  Gestational age during CMV screening will be no later than 20 weeks based on clinical&#xD;
             information and evaluation of the earliest ultrasound.&#xD;
&#xD;
          -  Enrollment will occur no later than 20 weeks' gestation.&#xD;
&#xD;
          -  Singleton pregnancy. A twin pregnancy reduced to singleton (either spontaneously or&#xD;
             therapeutically) before 20 weeks' by project gestational age is acceptable.&#xD;
&#xD;
          -  English and Spanish-speaking women of any age will be offered enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Planned termination of pregnancy&#xD;
&#xD;
          -  Women with a previous child with congenital CMV&#xD;
&#xD;
          -  Intention of leaving the prenatal practice&#xD;
&#xD;
          -  Known major fetal anomalies or demise&#xD;
&#xD;
          -  Multiple gestation&#xD;
&#xD;
          -  Known HIV infection&#xD;
&#xD;
          -  Primary CMV infection, as determined by a positive IgM antibody, a positive IgG&#xD;
             antibody and low IgG avidity or positive IgM antibody and negative IgG antibody&#xD;
&#xD;
          -  An old and a recent CMV infection, as determined by a positive IgM antibody, positive&#xD;
             IgG antibody and high IgG avidity.&#xD;
&#xD;
          -  Non-Spanish or English speaking&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brenna Anderson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Women &amp; Infants Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Women and Infants Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>March 18, 2013</study_first_submitted>
  <study_first_submitted_qc>March 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2013</study_first_posted>
  <last_update_submitted>June 1, 2015</last_update_submitted>
  <last_update_submitted_qc>June 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Women and Infants Hospital of Rhode Island</investigator_affiliation>
    <investigator_full_name>Brenna Hughes</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Intervention studies</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Cytomegalovirus Infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

